> ## Content Index > Fetch the complete content index at: https://newsletters.qs.com/llms.txt > Use this file to discover other available public pages before exploring further. # 💊 Health Futures #42 - URL: https://newsletters.qs.com/health-futures-42/ - Published: 2024-11-04T12:30:29.000Z - Updated: 2024-11-04T12:30:29.000Z - Description: HolonIQ's Health Newsletter covers the latest developments in drug production, AI in health, and biotechnology and highlights the week's top skills and health deals. - Author: QS - Tags: Health Skills **Happy Monday 👋** Eli Lilly and Johnson & Johnson are[ seeking](https://www.biospace.com/drug-development/lilly-and-j-j-face-off-in-crohns-disease-with-phase-iii-readouts-at-acg-2024?ref=newsletters.qs.com) to expand the use of their respective drugs, Omvoh and Tremfya, to treat Crohn's disease providing new treatment options for patients. Oracle[ introduced ](https://www.cnbc.com/2024/10/29/oracle-announces-new-ai-powered-electronic-health-record.html?ref=newsletters.qs.com)a new EHR that leverages AI to streamline workflows and improve patient care. This innovation has the potential to revolutionize healthcare delivery and enhance patient outcomes. AbbVie[ partners](https://www.pharmaceutical-technology.com/news/abbvie-richter-partner-neuropsychiatric/?cf-view&ref=newsletters.qs.com) with Gedeon Richter to develop new treatments for neuropsychiatric disorders. The agreement focuses on identifying, co-developing, and licensing new targets to tackle these specific conditions. A health acquisition, AbbVie acquired Aliada Therapeutics for [$1.4B](https://www.finsmes.com/2024/10/abbvie-to-acquire-aliada-therapeutics.html?ref=newsletters.qs.com). This acquisition enables AbbVie to accelerate the development of new therapies for Alzheimer's disease and other neurological disorders. **What's new?** *HolonIQ’s new* [*Green Skills Map*](https://www.greenskills.org/?ref=newsletters.qs.com) *and Workforce section reveal industry-wide sustainability skills and jobs, as well as workforce development initiatives, supporting upskilling for a sustainable economy.* ## 💊 Drug Production ⚕️ **Eli Lilly and Johnson & Johnson are** [**seeking**](https://www.biospace.com/drug-development/lilly-and-j-j-face-off-in-crohns-disease-with-phase-iii-readouts-at-acg-2024?ref=newsletters.qs.com) **label expansions.** Respectively the drugs Omvoh and Tremfya are used for treating Crohn's disease leading to new treatment options for the patients. 🩺 **JW Pharmaceutical** [**partnered**](https://www.mk.co.kr/en/it/11153233?ref=newsletters.qs.com) **with Tempus AI.** This partnership aims to accelerate the development of new anticancer drugs, by using AI and patient data hoping to identify effective treatments faster. 🧑‍⚕️ **NICE** [**expanded**](https://pharmaphorum.com/news/joy-nice-lifts-restrictions-myeloma-drug-elrexfio?ref=newsletters.qs.com) **access to Elrexfio, a treatment for multiple myeloma.** This initiative to ease restrictions on drug eligibility will benefit patients in England and Wales. ## 🌐 AI in Health 🤖 **WELL Health Technologies and HEALWELL AI**[ **expanded**](https://www.prnewswire.com/news-releases/well-health-and-healwell-ai-expand-strategic-alliance-agreement-to-develop-an-ai-enhanced-clinical-trials-program-to-accelerate-innovation-and-improve-patient-outcomes-302289792.html?ref=newsletters.qs.com) **their partnership.** The alliance's expansion aims to launch and manage clinical trial sites at WELL’s clinic locations across Canada by leveraging AI technology to streamline the clinical research process. 📋 **Oracle**[ **introduced**](https://www.cnbc.com/2024/10/29/oracle-announces-new-ai-powered-electronic-health-record.html?ref=newsletters.qs.com) **a new EHR that supports AI to streamline workflows and improve patient care.** EHR change courses from traditional EHR systems by using AI-powered voice commands and automated documentation allowing physicians to spend time with the patients. ⏳ **SandboxAQ and Sanofi**[ **partnered**](https://www.prnewswire.com/news-releases/sandboxaq-selected-by-sanofi-for-quantitative-ai-driven-biomarker-identification-302290471.html?ref=newsletters.qs.com) **to use AI to identify biomarkers in clinical development.** The partnership uses AI to accelerate drug discovery and development by identifying biomarkers able to predict patient response to treatment and improve clinical trial design. ## 🧬 Biotechnology 🧪 **AION Labs**[ **launched**](https://www.prnewswire.com/news-releases/aion-labs-launches-new-ai-startup-to-accelerate-identification-of-active-small-molecules-for-drug-discovery-302289831.html?ref=newsletters.qs.com) **ProPhet.** ProPhet, a new startup focused on using AI to discover new drug molecules. ProPhet's technology aims to address the challenges of traditional drug discovery by accelerating the identification of potential drug candidates. 🔬 **Idorsia and Neurocrine ended their**[ **collaboration**](https://www.fiercebiotech.com/biotech/neurocrine-idorsia-part-ways-2-years-after-collabs-double-phase-2-fails?ref=newsletters.qs.com) **on the development of the drug candidate, NBI-827104\.** It failed to meet its primary endpoints in two phase 2 clinical trials for essential tremor and pediatric epileptic encephalopathy. 🏥 **AbbVie and Gedeon Richter extended their** [**partnership**](https://www.pharmaceutical-technology.com/news/abbvie-richter-partner-neuropsychiatric/?cf-view&ref=newsletters.qs.com) **to develop new treatments for neuropsychiatric disorders.** The companies will collaborate on research and development activities, to discover and develop novel therapies for patients with these conditions. ## **🛠️** Skills and Workforce *With reskilling and upskilling playing a key role in closing workforce gaps, HolonIQ is now tracking these impactful initiatives shaping the health industry. Read on for this week’s insights.* **👨‍⚕️ The Australian Government launched new training initiatives to address critical skills shortages, investing** [**$4.4M into projects under the Skills Solutions Partnerships program**](https://www.miragenews.com/new-training-to-grow-and-upskill-critical-1345367/?ref=newsletters.qs.com)**.** Targeted at high-priority fields—manufacturing, economics, construction, healthcare, and social services—the program aims to equip the workforce with essential skills for growth and adaptation in these key areas. By providing customized training, the initiative supports workforce expansion and helps bridge skills gaps, addressing immediate industry needs while promoting long-term economic resilience. This commitment underscores the government's dedication to bolstering job readiness and supporting sustainable industry development across critical sectors. [![](https://storage.ghost.io/c/f1/d4/f1d411df-6f49-4c75-a302-f8c9e9f59495/content/images/2024/10/Screenshot-2024-10-25-102758-1.png)](https://www.greenskills.org/?ref=newsletters.qs.com) HolonIQ has also launched the [Green Skills Map](http://greenskills.org/?ref=newsletters.qs.com), an open-source framework initiated for the purpose of cataloging, evaluating, and contextualizing the different components of the rapidly expanding field of green jobs. This comprehensive taxonomy will serve as a resource for understanding the full spectrum and complexity of green skills required across various sectors, thereby enabling a cohesive approach toward achieving net zero and decarbonizing the global economy. Green Skills Map spans 11 areas, 54 sub-areas, and 243 green skills clusters. A snippet of the map covering four areas has been included above. Explore the full map on [greenskills.org](http://greenskills.org/?ref=newsletters.qs.com). ## **💰** Deals of the Week 🦠 **AbbVie** acquired **Aliada Therapeutics** for[ $1.4B](https://www.finsmes.com/2024/10/abbvie-to-acquire-aliada-therapeutics.html?ref=newsletters.qs.com) to expand its pipeline of CNS drug development. 🧬 **Seaport Therapeutics** raised [$225M](https://www.biospectrumasia.com/news/98/25098/australia-based-seaport-therapeutics-secures-225-m-funding-to-develop-neuropsychiatric-medicines-using-prodrug-technology.html?ref=newsletters.qs.com) in a Series B funding round. The funds will be used to advance its lead drug candidate into clinical trials and further develop its Glyph technology platform. 💉 **Kivu Bioscience** secured[ a $92M](https://www.citybiz.co/article/618939/kivu-bioscience-raises-92m-series-a/?ref=newsletters.qs.com) Series A financing round. The funding will be used to advance multiple oncology programs in the clinic. 🩹 **Agomab Therapeutics** raised [$89M](https://www.finsmes.com/2024/10/agomab-raises-89m-in-series-d-financing.html?ref=newsletters.qs.com) in Series D funding. The funds will be used further to advance the ongoing clinical development of its lead candidate. 🧫 **Aignostics** raised [$34M](https://www.finsmes.com/2024/10/aignostics-raises-34m-in-series-b-funding.html?ref=newsletters.qs.com) in Series B funding. The funds will be used to build new product offerings for biopharmaceutical clients --- **Thank you for reading. Have a great week ahead!** Have some feedback or suggestions? Let us know at hello@holoniq.com [ ](https://newsletters.qs.com/psychedelic-mental-health-treatments-south-asia-health-tech-100-2/)